Background
Clomiphene was synthesized in the late 1950s and approved for clinical use in the United States in 1967, making it one of the first oral agents developed for ovulation induction. It provided a lower-cost, orally administered alternative to injectable gonadotropins and became a foundational therapy for anovulatory infertility, particularly PCOS. Recognition of clomiphene's SERM mechanism explained its tissue-selective estrogenic and antiestrogenic effects. In recent decades, aromatase inhibitors (particularly letrozole) and advances in assisted reproductive technology have refined clinical practice, but clomiphene retains a role for selected patients globally. Off-label use in men for secondary hypogonadism and post-androgen recovery has grown alongside interest in fertility-preserving testosterone management.
Evidence snapshot
Clomiphene citrate is extensively studied for ovulation induction in anovulatory infertility and has been a first-line oral agent for women with PCOS for decades. The PPCOS II randomized trial (Legro et al., NEJM 2014) demonstrated higher cumulative live-birth rates with letrozole than with clomiphene in women with PCOS, shifting first-line preferences in many guidelines. Clomiphene remains effective for a broad population of anovulatory women and is widely used globally.
Evidence for clomiphene in men centers on its ability to raise endogenous LH, FSH, and testosterone without suppressing spermatogenesis — unlike exogenous testosterone. Available data come from small randomized trials, cohort studies, and meta-analyses; biochemical testosterone improvements are consistent, but high-quality long-term outcome data on cardiovascular health and prostate risk are lacking.
Safety data in women are well characterized: the main clinical risks are ovarian hyperstimulation syndrome (uncommon at standard doses), multiple gestation (increased twin rate), and transient vasomotor and visual symptoms. In men, the side-effect profile is similar in character but long-term safety evidence is thinner. Because clomiphene is a racemic mixture of enclomiphene (more antiestrogenic, shorter-acting) and zuclomiphene (more estrogenic, longer-acting), interindividual variability in response and washout timing is clinically relevant.
Bioavailability and pharmacokinetics
Clomiphene is orally administered and well absorbed from the gastrointestinal tract. Hepatic metabolism yields active metabolites; zuclomiphene has a substantially longer half-life than enclomiphene and accumulates with repeated dosing. This prolonged presence of the more estrogenic isomer can extend physiological effects beyond the five-day dosing window and explains why washout prior to conception attempts may take longer than the nominal half-life of the racemate would suggest. Interindividual differences in hepatic metabolism contribute to variability in clinical response.
Populations studied
The largest and most rigorous evidence base concerns women with anovulatory infertility, particularly PCOS. Landmark randomized trials compared clomiphene with letrozole (PPCOS II) and with injectable gonadotropins. Evidence in men derives from smaller randomized trials, case series, and observational cohorts assessing serum testosterone, gonadotropins, semen parameters, and symptom outcomes. Pediatric, elderly, and hepatically impaired populations have limited dedicated trial data.
Long-term safety and monitoring
Short-term adverse events — hot flashes, visual symptoms, and ovarian enlargement — are well characterized. Historical concern about a possible link between ovarian stimulation and ovarian cancer has not been confirmed as causal in large systematic reviews for typical short-term therapeutic use, though individualized risk assessment remains appropriate. For men on extended clomiphene therapy, long-term cardiovascular and prostate outcome data are limited; periodic monitoring of serum testosterone, hematocrit, liver function, and prostate health is reasonable clinical practice.
When clomiphene may be preferred or avoided
Clomiphene is appropriate when oral, lower-cost ovulation induction is the goal and contraindications are absent. Contraindications include estrogen-dependent neoplasia, uncontrolled thyroid or adrenal dysfunction, organic intracranial lesions, and pre-existing visual disturbances. Letrozole is preferred over clomiphene in many women with PCOS based on superior live-birth rates in the PPCOS II trial, but clomiphene remains a valid option in settings where letrozole is unavailable or where patient factors favor its use. In men, clomiphene is chosen over exogenous testosterone when fertility preservation is a priority.
Compound variations
Racemic clomiphene (standard clomiphene citrate)
Commercial clomiphene is a racemic mixture of enclomiphene and zuclomiphene with the combined clinical profile established in decades of trials.
Common use case
Standard ovulation induction and off-label uses where the established clinical evidence base is the primary consideration.
Dosage note
Ovulation induction: 50–150 mg/day for 5 days. Male off-label dosing: 25–50 mg every other day or daily.
Enclomiphene (trans-isomer)
Enclomiphene is the predominantly antiestrogenic isomer with a shorter half-life. It has been evaluated as a targeted treatment for secondary male hypogonadism, with the goal of raising testosterone while minimizing estrogenic side effects.
Common use case
Investigational and specialist use for secondary male hypogonadism where reducing estrogenic side effects relative to the racemate is desired.
Dosage note
Clinical trial dosing has varied; not widely available as a marketed prescription product in most regions — use under specialist supervision only.
Zuclomiphene (cis-isomer)
Zuclomiphene is the more estrogenic, longer-acting isomer present in racemic clomiphene. Its accumulation with repeated dosing contributes to prolonged effects and some estrogenic side effects observed clinically.
Common use case
Not used separately in clinical practice; understanding its distinct pharmacology explains interindividual variability in response duration and side-effect profile.
Dosage note
No independent dosing — present as a component of racemic clomiphene only.
Dosage and best practices
Dosage principles
- Female ovulation induction (standard regimen): 50 mg orally once daily for 5 days, starting on cycle day 3–5. If ovulation is not achieved, the dose may be increased to 100 mg/day or 150 mg/day for 5 days in subsequent cycles. The 50–150 mg/day for 5 days range represents the evidence-based and label-supported span.
- Male hypogonadism (off-label): 25–50 mg orally every other day or daily, individualized to response. Published studies have used 25 mg every other day up to 50 mg daily; practitioner monitoring of serum testosterone, LH, FSH, and semen parameters is standard practice.
- Treatment duration — women: Clinical practice generally limits empirical clomiphene use to 3–6 ovulatory cycles before reassessing. Continuing beyond six cycles without pregnancy warrants evaluation for additional contributing factors.
- Treatment duration — men: Reassess serum testosterone and symptoms at 4–8 weeks after initiation. Long-term use should include periodic monitoring of liver function, hematocrit, prostate health, and visual symptoms given limited long-term safety data.
Best practices
- Conduct baseline evaluation before starting: pregnancy test and pelvic ultrasound in women; serum testosterone, LH, FSH, and semen analysis in men.
- Monitor ovulation response in women with midluteal serum progesterone or follicular ultrasound; monitor serum testosterone and gonadotropins in men at 4–8 weeks.
- Counsel on timing of intercourse or insemination relative to the ovulation window and discuss the risk of multiple gestation before initiating in women.
- Discontinue and evaluate promptly for new visual disturbances, significant abdominal pain (possible ovarian hyperstimulation), or severe mood changes.
Literature and references
Letrozole versus clomiphene for infertility in the polycystic ovary syndrome
The New England journal of medicine • 2014
Large randomized trial (PPCOS II) demonstrating higher cumulative live-birth rates with letrozole than clomiphene in women with PCOS, which influenced first-line therapy guidelines in many countries.
Clomiphene citrate prescribing information
U.S. FDA / DailyMed • 2016
Official U.S. prescribing information summarizing approved indications, dosing regimens, contraindications, adverse reactions, and monitoring requirements for clomiphene citrate.
Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone
Fertility and sterility • 2014
Phase II randomized trial in men with secondary hypogonadism: enclomiphene citrate raised morning testosterone to levels similar to topical testosterone gel, increased LH and FSH, and conserved sperm counts.
Efficacy of clomiphene citrate and tamoxifen on pregnancy rates in idiopathic male subfertility: A systematic review and meta-analysis
Asian journal of urology • 2025
Systematic review and meta-analysis evaluating clomiphene citrate and tamoxifen versus placebo on natural pregnancy rates in idiopathic male subfertility, with hormone levels among the secondary outcomes.
Common questions
How long does clomiphene take to work?
In women, ovulation typically occurs 5–10 days after the last pill of a five-day course. In men, measurable increases in serum testosterone are generally seen within 4–8 weeks of starting therapy.
Does clomiphene preserve fertility in men?
Unlike exogenous testosterone — which suppresses LH, FSH, and intratesticular testosterone and impairs spermatogenesis — clomiphene raises endogenous gonadotropins and testosterone while maintaining testicular stimulation. It is used off-label in men with secondary hypogonadism who want to preserve fertility, though semen parameter responses vary and should be monitored.
What is the risk of multiple pregnancy?
Clomiphene increases the rate of multiple gestation, most commonly twins, compared with natural conception. The absolute risk depends on the number of mature follicles and individual patient factors; this should be discussed before initiating treatment for fertility.
Can clomiphene be used after a course of exogenous testosterone?
Clomiphene is used off-label in some cases to stimulate endogenous testosterone recovery after exogenous androgen exposure, by increasing LH and FSH. Response varies; monitoring of serum hormones and semen parameters is recommended, and guidance from a specialist is advisable.
When should I stop clomiphene and contact a clinician?
Discontinue and seek evaluation for any new visual disturbances, severe or worsening abdominal pain, or signs of significant ovarian enlargement. Also consult your clinician if ovulation has not occurred after several cycles at the maximum tolerated dose, or if side effects are interfering with daily functioning.